Janux Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| JANUX THERAPEUTICS, INC. | ||
| Date: February 26, 2026 | By: | /s/ David Campbell, Ph.D. |
|---|---|---|
| David Campbell, Ph.D. | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Campbell and Janeen Doyle, and each of them, his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ David Campbell, Ph.D. | President and Chief Executive Officer and Director | February 26, 2026 |
| David Campbell, Ph.D. | (Principal Executive and Financial Officer) | |
| /s/ Janeen Doyle | Chief Corporate and Business Development Officer | February 26, 2026 |
| Janeen Doyle | (Principal Accounting Officer) | |
| /s/ Ron Barrett, Ph.D. | Chairperson of the Board of Directors | February 26, 2026 |
| Ron Barrett, Ph.D. | ||
| /s/ Vickie Capps | Director | February 26, 2026 |
| Vickie Capps | ||
| /s/ Eric Dobmeier | Director | February 26, 2026 |
| Eric Dobmeier | ||
| /s/ Sheila Gujrathi, M.D. | Director | February 26, 2026 |
| Sheila Gujrathi, M.D. | ||
| /s/ Natasha Hernday | Director | February 26, 2026 |
| Natasha Hernday | ||
| /s/ Winston Kung | Director | February 26, 2026 |
| Winston Kung | ||
| /s/ Alana McNulty | Director | February 26, 2026 |
| Alana McNulty | ||
| /s/ Jake Simson, Ph.D. | Director | February 26, 2026 |
| Jake Simson, Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.